Mineralys Therapeutics, Inc. (MLYS) Stock Statistics & Valuation Metrics

Mineralys Therapeutics, Inc. has a market cap or net worth of $922.23M. The enterprise value is $721.38M.

Mineralys Therapeutics, Inc. has 65,175,285 shares outstanding. The number of shares has decreased by -2.65% in one year.

Mineralys Therapeutics, Inc.’s return on equity (ROE) is -0.93 and return on invested capital (ROIC) is -100.60%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Mineralys Therapeutics, Inc. had revenue of 0.00 and earned -177.81M in profits. Earnings per share was -3.66.

In the last 12 months, operating cash flow was -4.89M and capital expenditures 0.00, giving a free cash flow of -4.89M billion.

Mineralys Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Mineralys Therapeutics, Inc. upcoming earnings date is Aug 11, 2025, After Close (Confirmed).

Mineralys Therapeutics, Inc. as a current ratio of 14.02, with Debt / Equity ratio of 0.00%

In the past 12 months, Mineralys Therapeutics, Inc. has paid 0.00 in taxes.

Mineralys Therapeutics, Inc. EV to EBITDA ratio is -2.72, with an EV/FCF ratio of -2.91.

Mineralys Therapeutics, Inc. has $343.03M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$343.03M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Mineralys Therapeutics, Inc. is $36.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy